Brigham Does Not Contest Plaintiffs’ Offers of Proof as Morcellation Cases Proceed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This article is part of The Cancer Letter's How Medical Devices Do Harm series.

BRIGHAM & WOMEN’S HOSPITAL chose not to contest the plaintiffs’ offers of proof in two medical malpractice lawsuits against the Boston hospital at a Massachusetts tribunal May 13.

The two lawsuits related to power morcellation will now be allowed to proceed. The suits were filed by Richard Kaitz and Hooman Noorchashm, whose wives, Erica Kaitz and Amy Reed, had the controversial minimally invasive surgery at Brigham in 2012 and 2013, respectively.

The procedure, which until recently was performed in an estimated 100,000 women annually in the U.S., is the focal point of a two-year debate that has divided the surgical field. When a previously undiagnosed malignant tumor—usually a sarcoma—is present, the procedure spreads the cancerous tissue, upstaging the disease (The Cancer Letter, How Medical Devices Do Harm).

Erica died Dec. 7, 2013 from metastatic leiomyosarcoma, and Reed, formerly an anesthesiologist at Beth Israel Deaconess Medical Center, is undergoing treatment for stage IV disease.

“It’s a rare case that the defendant does not contest the plaintiff’s offer of proof at the tribunal stage,” said Tom Greene, the attorney representing Kaitz and Noorchashm’s families. Brigham did not respond to an email from The Cancer Letter by deadline.

Massachusetts law requires that a tribunal—consisting of a judge, an attorney, and a physician—review medical malpractice cases to screen out lawsuits that are not supported by clinical evidence or fact. The process determines whether there is sufficient evidence for the case to proceed.

According to the Massachusetts Medical Society, tribunals screen out approximately 16 percent of all medical malpractice cases in the state.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login